Cargando…
Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines
BACKGROUND: IMMUNEPOTENT-CRP® (I-CRP) is a bovine dialyzable leukocyte extract containing transfer factor. It is a cost-effective, unspecific active immunotherapy that has been used in patients with non-small cell lung cancer (NSCLC) as an adjuvant to reduce the side-effects of chemotherapy and radi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768219/ https://www.ncbi.nlm.nih.gov/pubmed/31579619 http://dx.doi.org/10.7717/peerj.7759 |
_version_ | 1783455068396191744 |
---|---|
author | Martinez-Torres, Ana Carolina Gomez-Morales, Luis Martinez-Loria, Alan B. Uscanga-Palomeque, Ashanti Concepcion Vazquez-Guillen, Jose Manuel Rodriguez-Padilla, Cristina |
author_facet | Martinez-Torres, Ana Carolina Gomez-Morales, Luis Martinez-Loria, Alan B. Uscanga-Palomeque, Ashanti Concepcion Vazquez-Guillen, Jose Manuel Rodriguez-Padilla, Cristina |
author_sort | Martinez-Torres, Ana Carolina |
collection | PubMed |
description | BACKGROUND: IMMUNEPOTENT-CRP® (I-CRP) is a bovine dialyzable leukocyte extract containing transfer factor. It is a cost-effective, unspecific active immunotherapy that has been used in patients with non-small cell lung cancer (NSCLC) as an adjuvant to reduce the side-effects of chemotherapy and radiotherapy, and has shown cytotoxic activity in vitro on different cancer cell lines. However, its mechanism of action against lung cancer cells has not been assessed. Therefore, the objective of this work was to assess the cytotoxic mechanism of I-CRP on lung cancer cell lines. METHODS: We assessed cell viability through MTT assay on the NSCLC cell lines A549, A427, Calu-1, and INER-51 after treatment with I-CRP. To further understand the mechanisms of cell viability diminution we used fluorescence-activated cell sorting to evaluate cell death (annexin-V and propidium iodide [PI] staining), cell cycle and DNA degradation (PI staining), mitochondrial alterations (TMRE staining), and reactive oxygen species (ROS) production (DCFDA staining). Additionally, we evaluated caspase and ROS dependence of cell death by pretreating the cells with the pan-caspase inhibitor Q-VD-OPH and the antioxidant N-acetylcysteine (NAC), respectively. RESULTS: Our data shows that I-CRP is cytotoxic to NSCLC cell lines in a dose and time dependent manner, without substantial differences between the four cell lines tested (A549, A427, Calu-1, and INER-51). Cytotoxicity is induced through regulated cell death and cell cycle arrest induction. I-CRP-induced cell death in NSCLC cell lines is characterized by DNA degradation, mitochondrial damage, and ROS production. Moreover, cell death is independent of caspases but relies on ROS production, as it is abrogated with NAC. CONCLUSION: Altogether, these results improve the knowledge about the cytotoxic activity of I-CRP on NSCLC cells, indicating that cell death, cell cycle arrest, DNA degradation and mitochondrial damage are important features, while ROS play the main role for I-CRP mediated cytotoxicity in lung cancer cells. |
format | Online Article Text |
id | pubmed-6768219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67682192019-10-02 Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines Martinez-Torres, Ana Carolina Gomez-Morales, Luis Martinez-Loria, Alan B. Uscanga-Palomeque, Ashanti Concepcion Vazquez-Guillen, Jose Manuel Rodriguez-Padilla, Cristina PeerJ Cell Biology BACKGROUND: IMMUNEPOTENT-CRP® (I-CRP) is a bovine dialyzable leukocyte extract containing transfer factor. It is a cost-effective, unspecific active immunotherapy that has been used in patients with non-small cell lung cancer (NSCLC) as an adjuvant to reduce the side-effects of chemotherapy and radiotherapy, and has shown cytotoxic activity in vitro on different cancer cell lines. However, its mechanism of action against lung cancer cells has not been assessed. Therefore, the objective of this work was to assess the cytotoxic mechanism of I-CRP on lung cancer cell lines. METHODS: We assessed cell viability through MTT assay on the NSCLC cell lines A549, A427, Calu-1, and INER-51 after treatment with I-CRP. To further understand the mechanisms of cell viability diminution we used fluorescence-activated cell sorting to evaluate cell death (annexin-V and propidium iodide [PI] staining), cell cycle and DNA degradation (PI staining), mitochondrial alterations (TMRE staining), and reactive oxygen species (ROS) production (DCFDA staining). Additionally, we evaluated caspase and ROS dependence of cell death by pretreating the cells with the pan-caspase inhibitor Q-VD-OPH and the antioxidant N-acetylcysteine (NAC), respectively. RESULTS: Our data shows that I-CRP is cytotoxic to NSCLC cell lines in a dose and time dependent manner, without substantial differences between the four cell lines tested (A549, A427, Calu-1, and INER-51). Cytotoxicity is induced through regulated cell death and cell cycle arrest induction. I-CRP-induced cell death in NSCLC cell lines is characterized by DNA degradation, mitochondrial damage, and ROS production. Moreover, cell death is independent of caspases but relies on ROS production, as it is abrogated with NAC. CONCLUSION: Altogether, these results improve the knowledge about the cytotoxic activity of I-CRP on NSCLC cells, indicating that cell death, cell cycle arrest, DNA degradation and mitochondrial damage are important features, while ROS play the main role for I-CRP mediated cytotoxicity in lung cancer cells. PeerJ Inc. 2019-09-27 /pmc/articles/PMC6768219/ /pubmed/31579619 http://dx.doi.org/10.7717/peerj.7759 Text en ©2019 Martinez-Torres et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Cell Biology Martinez-Torres, Ana Carolina Gomez-Morales, Luis Martinez-Loria, Alan B. Uscanga-Palomeque, Ashanti Concepcion Vazquez-Guillen, Jose Manuel Rodriguez-Padilla, Cristina Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines |
title | Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines |
title_full | Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines |
title_fullStr | Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines |
title_full_unstemmed | Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines |
title_short | Cytotoxic activity of IMMUNEPOTENT CRP against non-small cell lung cancer cell lines |
title_sort | cytotoxic activity of immunepotent crp against non-small cell lung cancer cell lines |
topic | Cell Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768219/ https://www.ncbi.nlm.nih.gov/pubmed/31579619 http://dx.doi.org/10.7717/peerj.7759 |
work_keys_str_mv | AT martineztorresanacarolina cytotoxicactivityofimmunepotentcrpagainstnonsmallcelllungcancercelllines AT gomezmoralesluis cytotoxicactivityofimmunepotentcrpagainstnonsmallcelllungcancercelllines AT martinezloriaalanb cytotoxicactivityofimmunepotentcrpagainstnonsmallcelllungcancercelllines AT uscangapalomequeashanticoncepcion cytotoxicactivityofimmunepotentcrpagainstnonsmallcelllungcancercelllines AT vazquezguillenjosemanuel cytotoxicactivityofimmunepotentcrpagainstnonsmallcelllungcancercelllines AT rodriguezpadillacristina cytotoxicactivityofimmunepotentcrpagainstnonsmallcelllungcancercelllines |